High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis.

Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis (2007) 2.76

Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet (2009) 2.23

Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ (2003) 2.12

Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol (2007) 1.92

1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol (2011) 1.67

Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr (2008) 1.49

Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep (2010) 1.43

Vitamin D in health and disease: current perspectives. Nutr J (2010) 1.31

Vitamin D and multiple sclerosis: an update. Nutr Rev (2008) 1.25

Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab (2005) 1.17

Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J Biol Chem (2010) 1.16

Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol (2009) 1.08

The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol (2009) 1.07

Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci (2012) 1.04

Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab (2011) 1.02

Vitamin D level: is it related to disease activity in inflammatory joint disease? Rheumatol Int (2009) 0.92

Vitamin D receptor gene polymorphisms in multiple sclerosis patients in northwest Greece. J Negat Results Biomed (2011) 0.92

Bone health in multiple sclerosis. Osteoporos Int (2011) 0.90

Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther Adv Neurol Disord (2013) 0.89

Vitamin D status and concomitant autoimmunity in celiac disease. J Clin Gastroenterol (2013) 0.85

Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol (2011) 0.85

Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol (2009) 0.84

Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus. Rheumatology (Oxford) (2013) 0.84

Bone loss and fractures in multiple sclerosis: focus on epidemiologic and physiopathological features. Int J Gen Med (2011) 0.83

A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis. Neurology (2012) 0.83

Association of serum 25(OH) vitamin D3 concentration with severity of multiple sclerosis. Iran J Neurol (2012) 0.83

Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study. PLoS One (2012) 0.82

Positive association of vitamin D receptor gene variations with multiple sclerosis in South East Iranian population. Biomed Res Int (2015) 0.80

Bone mineral density in ambulatory patients with multiple sclerosis. Neurol Sci (2011) 0.79

Effect of high-dose vitamin D3 intake on ambulation, muscular pain and bone mineral density in a woman with multiple sclerosis: a 10-year longitudinal case report. Int J Mol Sci (2012) 0.78

Vitamin d3 concentration correlates with the severity of multiple sclerosis. Int J Prev Med (2013) 0.78

Multiple sclerosis. Glob Adv Health Med (2013) 0.78

What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year? J Neurol (2012) 0.77

Serum vitamin d levels in Indian patients with multiple sclerosis. Indian J Clin Biochem (2012) 0.77

Bone health in patients with multiple sclerosis. J Osteoporos (2011) 0.76

Nutritional factors and aging in demyelinating diseases. Genes Nutr (2013) 0.76

Body composition in multiple sclerosis. Hippokratia (2013) 0.76

Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitude-dependent autoimmune diseases. Genes Immun (2016) 0.76

Assessment of bone densitometry in Iranian patients with multiple sclerosis: A case-control study. Iran J Neurol (2013) 0.75

Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study. BMC Neurol (2016) 0.75

Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis. Mult Scler Int (2016) 0.75

Association between serum biochemical levels, related to bone metabolism and Parkinson's disease. J Res Med Sci (2013) 0.75

Comparison of serum vitamin D level in multiple sclerosis patients, their siblings, and healthy controls. Iran J Neurol (2015) 0.75

Bone loss with multiple sclerosis: effect of glucocorticoid use and functional status. Iran Red Crescent Med J (2011) 0.75

Serum 25-hydroxyvitamin D3 concentration in Iranian patients with Parkinson's disease. Iran J Neurol (2013) 0.75

Vitamin D status in men with psoriatic arthritis: a case-control study. Osteoporos Int (2015) 0.75

The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18

Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14

A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996) 6.03

RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85

Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17

The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27

Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet (1976) 4.24

Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88

Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab (1997) 3.00

An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int (2001) 2.94

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 2.78

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 2.71

Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70

Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res (2001) 2.65

Recent life events, cortisol, dehydroepiandrosterone and the onset of major depression in high-risk adolescents. Br J Psychiatry (2000) 2.43

Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr (1998) 2.37

Prevention of spinal osteoporosis in oophorectomised women. Lancet (1980) 2.34

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34

Endogenous steroids and financial risk taking on a London trading floor. Proc Natl Acad Sci U S A (2008) 2.22

Two types of astrocytes in cultures of developing rat white matter: differences in morphology, surface gangliosides, and growth characteristics. J Neurosci (1983) 2.18

C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab (2000) 2.14

Anabolic actions of parathyroid hormone on bone. Endocr Rev (1993) 2.13

Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax (2002) 2.12

Psychoendocrine antecedents of persistent first-episode major depression in adolescents: a community-based longitudinal enquiry. Psychol Med (2003) 2.07

Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res (1997) 1.98

Fracture history and bone loss in patients with MS. Neurology (1998) 1.97

Pathogenesis of osteoporosis. Lancet (1993) 1.93

The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85

Importance of precision in bone density measurements. J Clin Densitom (2001) 1.82

The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol (1984) 1.80

Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J (1973) 1.79

Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology (1986) 1.78

Immunologic responses in malnourished children. Am J Clin Nutr (1975) 1.78

Isolation of a cDNA clone encoding subunit IV of human cytochrome c oxidase. Gene (1987) 1.76

Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol (2003) 1.74

Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia. Brain (2004) 1.63

Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int (2009) 1.63

Chloramphenicol-induced changes in the synthesis of ribosomal, transfer, and messenger ribonucleic acids in Escherichia coli B/r. J Bacteriol (1977) 1.62

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57

Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med (1997) 1.56

On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab (1999) 1.53

Progeston therapy for menstrually related aphthae. Int J Oral Surg (1978) 1.52

The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab (1990) 1.51

A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler (1999) 1.50

Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med (1978) 1.50

Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A (2000) 1.47

Decreased bactericidal activity of leukocytes of stressed newborn infants. Pediatrics (1975) 1.45

Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int (2008) 1.44

Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci U S A (1998) 1.42

Exogenous calciferol (vitamin D) and vitamin D endocrine status among elderly nursing home residents in the New York City area. J Am Geriatr Soc (1993) 1.42

Constant mineralization density distribution in cancellous human bone. Bone (2003) 1.41

Therapeutic controversy: Estrogen replacement in menopause. J Clin Endocrinol Metab (1996) 1.41

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology (2001) 1.41

Adrenal steroid secretion and major depression in 8- to 16-year-olds, III. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression. Psychol Med (1998) 1.41

Trauma, post-traumatic stress disorder, and war. Lancet (1998) 1.39

Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol (2007) 1.38

Bone response to termination of oestrogen treatment. Lancet (1978) 1.38

The redistribution of body sodium in women on long-term oestrogen therapy. Clin Sci Mol Med (1974) 1.38

Interaction of calcium nutrition and physical activity on bone mass in young women. J Bone Miner Res (1988) 1.37

Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol (1985) 1.37

Adrenal secretion during major depression in 8- to 16-year-olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Psychol Med (1996) 1.36

Histomorphometric assessment of bone mass, structure, and remodeling: a comparison between healthy black and white premenopausal women. J Bone Miner Res (1997) 1.36

Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A (1994) 1.35

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res (2001) 1.33

Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci (2002) 1.33

Regional changes in c-fos expression in the basal forebrain and brainstem during adaptation to repeated stress: correlations with cardiovascular, hypothermic and endocrine responses. Neuroscience (1995) 1.33

Multiple sclerosis susceptibility alleles in African Americans. Genes Immun (2009) 1.32

Mapping brain response to social stress in rodents with c-fos expression: a review. Stress (2002) 1.31

A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia (2009) 1.31

Morning cortisol as a risk factor for subsequent major depressive disorder in adult women. Br J Psychiatry (2000) 1.30

Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. Br J Psychiatry (2001) 1.30

The retinal pigment epithelium is the unique site of transthyretin synthesis in the rat eye. Invest Ophthalmol Vis Sci (1990) 1.27

Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain (2010) 1.27

Milk and bones. BMJ (1994) 1.27

Elementary schoolteachers' understanding of diabetes. Diabetes Educ (1987) 1.27

The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int (2014) 1.27

Pattern of the insulin-like growth factor II gene expression during rat embryogenesis. Development (1988) 1.26

Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med (1998) 1.25

Adaptation in patterns of c-fos expression in the brain associated with exposure to either single or repeated social stress in male rats. Eur J Neurosci (1998) 1.24

Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. J Pediatr Hematol Oncol (2001) 1.24

Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J (1980) 1.24

Quantitation of Ca ATPase, feet and mitochondria in superfast muscle fibres from the toadfish, Opsanus tau. J Muscle Res Cell Motil (1991) 1.24